Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.60 |
| ▸ | F10 | P00742 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10314627 | 0.93 | SMO (0.61) | SMODRD4PRKAA2KCNH2MCHR1 | |
| SCHEMBL1058114 | 0.91 | SMO (0.73) | SMOF10DRD4PRKAA2SIGMAR1 | |
| SCHEMBL10314629 | 0.90 | SMO (0.72) | SMOMCHR1 | |
| SCHEMBL1057379 | 0.84 | SMO (0.83) | SMO | |
| SCHEMBL1061668 | 0.84 | SMO (0.73) | SMODRD4PRKAA2 | |
| SCHEMBL1063456 | 0.83 | SMO (0.82) | SMOBRD4 | |
| SCHEMBL1061383 | 0.83 | SMO (0.74) | SMOF10DRD4SIGMAR1 | |
| SCHEMBL1058049 | 0.81 | SMO (0.86) | SMOMCHR1 | |
| SCHEMBL1083650 | 0.81 | F10 (0.47) | SMOF10DRD4 | |
| SCHEMBL1062738 | 0.80 | SMO (0.70) | SMOSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217176-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | SMO 1/4885F10 2252/4885DRD4 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.